OnabotulinumtoxinA Reduces Health Resource Utilization in Chronic Migraine: PREDICT Study.

Area of Science:

• Neurology
• Pharmacology

Background:

• The PREDICT study assessed the real-world effectiveness of onabotulinumtoxinA in treatment-naïve adults with chronic migraine (CM) in Canada.
• The study focused on health resource utilization, work productivity, and acute medication use associated with CM management.

Purpose of the Study:

• To descriptively assess health resource utilization, work productivity, and acute medication use in Canadian adults with chronic migraine receiving onabotulinumtoxinA.
• To evaluate the impact of onabotulinumtoxinA on key outcome measures in a real-world setting.

Main Methods:

• A prospective, observational, multicenter study involving adults naïve to onabotulinumtoxinA for chronic migraine.
• OnabotulinumtoxinA was administered every 12 weeks for up to 2 years. Data collected included health resource utilization, work productivity (using validated questionnaires), and daily acute medication use.

Main Results:

• 184 participants received onabotulinumtoxinA. Headache-related healthcare professional visits decreased from 96.2% to 76.8%, and diagnostic testing decreased from 37.5% to 9.9%.
• Mean emergency room/urgent care visits reduced from 2.5 to 1.4, and hospital admissions decreased from 4.0 to 1.0. Work productivity improved, with missed work hours decreasing from 6.1 to 3.0.
• Acute medication use declined from 15.2 to 9.1 days. No new safety concerns were identified.

Conclusions:

• Real-world data from the PREDICT study support the long-term benefits of onabotulinumtoxinA for chronic migraine in Canada.
• OnabotulinumtoxinA treatment effectively reduces health resource utilization, acute medication use, and enhances workplace productivity in this patient population.